Mounjaro vs Ozempic vs Supplements UK: Which Is Right for You in 2026?

Mounjaro (tirzepatide) delivers the strongest weight loss results at up to 22.5% body weight reduction, making it the most effective option for significant obesity. Ozempic (semaglutide) offers proven efficacy of around 15% weight loss with additional cardiovascular benefits. UK weight management supplements provide modest support of 1–3 kg but remain the most affordable and accessible choice. The right option depends on your BMI, medical history, budget, and treatment goals.

With so many choices on the market, how do you decide what is right for you? In this comprehensive guide, the BuseMedia Editorial Team examines the three major categories head-to-head: Mounjaro (tirzepatide), Ozempic (semaglutide), and the most popular weight management supplements available in the UK. We evaluate the clinical evidence, costs, side effects, accessibility, and realistic expectations for each — so you can have an informed conversation with your healthcare provider.

Understanding the Science: How These Treatments Work

To make a meaningful comparison, it helps to understand the biological mechanisms behind each option. Mounjaro and Ozempic both belong to the broader family of incretin-based therapies, but they differ in a fundamental way. Ozempic contains the active ingredient semaglutide, which mimics a single gut hormone called glucagon-like peptide-1 (GLP-1). GLP-1 slows gastric emptying, reduces appetite signals in the brain, and enhances insulin secretion in response to food. This mechanism has been extensively validated in the STEP clinical trial programme, which demonstrated that semaglutide 2.4 mg (marketed as Wegovy for weight management) can produce average weight reductions of approximately 15% of body weight over 68 weeks. For a broader overview of how these medications fit into modern treatment pathways, see our guide to GLP-1 weight loss injections.

Mounjaro, on the other hand, contains tirzepatide, a first-in-class molecule that activates two incretin receptors simultaneously: the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual-agonist approach appears to produce more pronounced effects on appetite suppression, insulin sensitivity, and fat metabolism. The landmark SURMOUNT-1 trial, published in the New England Journal of Medicine, showed that participants receiving the highest dose of tirzepatide (15 mg) lost an average of 22.5% of their body weight over 72 weeks — a result that surpassed anything previously achieved with pharmacotherapy alone. The SURMOUNT-1 data (PMID: 35658024) marked a turning point in how clinicians view the treatment of obesity as a chronic disease.

Weight management supplements, by contrast, rely on a wide variety of mechanisms — many of which have far more modest evidence behind them. Common UK supplement ingredients include glucomannan (a water-soluble dietary fibre that expands in the stomach to promote feelings of fullness), green tea extract (containing catechins and caffeine thought to mildly boost thermogenesis), conjugated linoleic acid (CLA), chromium picolinate (which may improve insulin sensitivity), and Garcinia cambogia (containing hydroxycitric acid). While some of these ingredients have shown statistically significant effects in clinical studies, the magnitude of weight loss is generally much smaller — typically in the range of 1–3 kg over several months. The NHS obesity treatment page provides further guidance on which approaches are supported by clinical evidence.

Clinical Efficacy: What the Evidence Actually Shows

When comparing these three categories, the most important question is straightforward: how much weight can a person realistically expect to lose?

Mounjaro (tirzepatide) has the strongest efficacy data of any weight management medication currently available. Across the SURMOUNT trial programme, participants on the 5 mg, 10 mg, and 15 mg doses achieved mean body weight reductions of approximately 16%, 21%, and 22.5% respectively, compared to roughly 2–3% with placebo. The SURMOUNT-2 trial specifically studied tirzepatide in people with both obesity and type 2 diabetes, and found weight loss of up to 14.7% — still substantially greater than comparators. These are not just statistically significant results; they represent clinically meaningful improvements in cardiometabolic risk factors including blood pressure, triglycerides, HbA1c, and waist circumference.

Ozempic (semaglutide 1 mg) is licensed primarily for type 2 diabetes, where the primary endpoint is glycaemic control rather than weight loss. However, participants in the SUSTAIN trials consistently lost between 4.5 and 6.5 kg on average. The higher-dose formulation, Wegovy (semaglutide 2.4 mg), is the weight-management-specific product and delivers stronger results: the STEP-1 trial demonstrated a mean weight loss of 14.9% over 68 weeks. It is important to note that Ozempic and Wegovy contain the same active ingredient at different doses and with different licensed indications. In UK clinical practice, some patients prescribed Ozempic for diabetes do experience significant weight loss as a secondary benefit. The STEP-1 trial results (PMID: 33567185) have been foundational in establishing semaglutide as a first-line anti-obesity medication.

Supplements consistently produce more modest outcomes. A Cochrane review of glucomannan found that it may contribute to short-term weight loss of around 0.8–1.5 kg more than placebo over 4–8 weeks. Green tea extract meta-analyses suggest a modest additional loss of approximately 1.3 kg over 12 weeks, although results are heterogeneous and many studies were conducted in East Asian populations, raising questions about generalisability. CLA supplements have shown mixed results, with some trials reporting reductions in body fat mass of around 0.05 kg per week. Chromium picolinate has limited evidence for meaningful weight loss in people without diabetes. In summary, while supplements may offer a small incremental benefit when combined with diet and exercise, they do not approach the efficacy of prescription incretin therapies. For more on building sustainable habits alongside any treatment, read our article on healthy weight management tips.

Side Effects, Safety, and Tolerability

No discussion of weight management treatments is complete without a frank assessment of side effects. Both Mounjaro and Ozempic share a common side-effect profile rooted in their gastrointestinal mechanism of action. The most frequently reported adverse events include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These side effects are typically most pronounced during the dose-escalation phase and tend to diminish over time as the body adapts. In the SURMOUNT and STEP trials, gastrointestinal events led to treatment discontinuation in approximately 4–7% of participants — meaning the vast majority were able to continue therapy.

There are, however, more serious safety considerations that require medical supervision. Both drug classes carry warnings about potential pancreatitis, although the absolute risk appears to be low. There have been theoretical concerns about thyroid C-cell tumours, based on rodent studies — which is why both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Gallbladder-related events, including cholelithiasis, have also been observed at higher rates in clinical trials, likely related to the rapid weight loss itself. Ongoing pharmacovigilance studies, including large-scale cardiovascular outcome trials like SELECT (PMID: 37385275), continue to monitor long-term safety outcomes.

Supplements are generally considered to have a milder side-effect profile, but this does not mean they are without risk. Glucomannan can cause bloating, flatulence, and in rare cases oesophageal obstruction if taken without sufficient water. High-dose green tea extract has been linked to reports of hepatotoxicity (liver damage), prompting the European Food Safety Authority (EFSA) to set a recommended upper limit of 800 mg of epigallocatechin gallate (EGCG) per day. CLA may cause gastrointestinal upset, and some evidence suggests it could worsen insulin resistance in certain individuals. Additionally, supplements in the UK are regulated as foods rather than medicines, meaning they undergo far less rigorous pre-market testing than prescription pharmaceuticals. Quality control issues — including inaccurate labelling and contamination — have been documented in independent analyses of supplement products. The WebMD guide to prescription weight loss drugs offers a useful comparison of how regulated medications differ from over-the-counter products.

Cost and Accessibility in the UK

One of the most significant practical differences between these options is cost and how you access them. This is a particularly important consideration in the UK, where the National Health Service (NHS) plays a central role in determining which treatments are available and to whom.

Ozempic has been available on NHS prescription for type 2 diabetes since its MHRA approval. The cost to the NHS is approximately £70–£85 per month depending on the dose. Its weight-management counterpart, Wegovy, received NICE approval for obesity treatment and became available through specialist weight management services, though access has been constrained by supply issues and strict eligibility criteria. Patients must typically have a BMI of 35 or above (or 30+ with a weight-related comorbidity) and have attempted behavioural interventions first. Privately, Wegovy prescriptions through licensed online clinics can cost between £150 and £300 per month.

Mounjaro received its MHRA licence for type 2 diabetes and has subsequently been evaluated by NICE for broader weight management indications. As of early 2026, tirzepatide is available both through NHS diabetes services and via private prescriptions for weight management. The private cost of Mounjaro in the UK typically ranges from £150 to £250 per month depending on dose and provider, although prices have been gradually decreasing as supply stabilises and competition increases. NICE technology appraisals have been broadly positive, recognising tirzepatide's superior efficacy relative to existing options, though NHS access for weight management specifically may still be limited by local commissioning arrangements and service capacity.

Supplements are by far the most accessible and affordable option. Glucomannan capsules can be purchased for as little as £8–£15 per month, green tea extract for £5–£12, and combination products for £15–£30. They require no prescription, no GP referral, and no eligibility criteria. This accessibility is both an advantage and a risk: it means anyone can purchase them, but it also means people may use them as a substitute for evidence-based medical treatment when they would genuinely benefit from clinical intervention.

Who Should Consider Each Option?

Choosing between these options is not simply a matter of picking the "best" one. The right choice depends on your individual medical history, the amount of weight you need to lose, your budget, your risk tolerance, and your relationship with your healthcare team.

Mounjaro (tirzepatide) may be most appropriate for individuals with significant obesity (BMI 30+) who have struggled with other interventions, particularly if they also have type 2 diabetes or prediabetes. Its dual-receptor mechanism offers the greatest average weight loss, and the glycaemic benefits are substantial. It is particularly worth discussing with your doctor if you need to lose a large amount of weight and are prepared to commit to a long-term treatment plan, as weight regain after discontinuation is common with all anti-obesity medications.

Ozempic or Wegovy (semaglutide) is an excellent option for individuals with type 2 diabetes seeking improved glycaemic control alongside weight loss, or for those who meet the criteria for obesity pharmacotherapy. Semaglutide also has the advantage of a longer track record and more extensive real-world safety data. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in patients with obesity and established cardiovascular disease — adding a powerful argument for its use in that population. If cardiovascular risk reduction is a priority, semaglutide currently has the stronger evidence base in this specific area.

Supplements may be a reasonable consideration for individuals who are mildly overweight, who do not have obesity-related comorbidities, and who are looking for modest additional support alongside a structured diet and exercise programme. They are not a substitute for medical treatment in clinical obesity, but they may play a small complementary role for some people. It is essential to choose products from reputable manufacturers, look for evidence of third-party testing, and be wary of exaggerated marketing claims. No supplement available in the UK has been shown to produce weight loss outcomes comparable to prescription GLP-1 or GIP/GLP-1 therapies.

Weight Regain and Long-Term Considerations

One of the most important — and often underappreciated — aspects of any weight management strategy is what happens in the long term. Research consistently shows that obesity is a chronic, relapsing condition, and that the body actively resists sustained weight loss through hormonal and metabolic adaptations.

The SURMOUNT-4 trial examined what happened when participants who had lost weight on tirzepatide were randomised to either continue the medication or switch to placebo. Those who discontinued tirzepatide regained approximately 14% of their body weight over the following 52 weeks, while those who continued maintained their losses. Similar patterns have been observed with semaglutide in the STEP-4 trial, where discontinuation led to regain of roughly two-thirds of lost weight within a year. These findings underscore that for most patients, incretin therapies need to be continued long-term to sustain their benefits — much like statins for cholesterol or antihypertensives for blood pressure.

This has significant implications for cost, NHS resource allocation, and patient expectations. If a medication must be taken indefinitely, its annual cost becomes a critical factor. It also means that lifestyle modifications — improved nutrition, regular physical activity, adequate sleep, and stress management — remain foundational. No medication eliminates the need for healthy behaviours; rather, the best outcomes arise when pharmacotherapy and lifestyle changes work in concert.

For supplements, the long-term picture is somewhat different. Because the weight loss achieved is typically modest, the degree of regain upon stopping is also smaller in absolute terms. However, the underlying principle is the same: any intervention works only as long as the overall energy balance supports weight management.

Navigating Prescriptions, Private Clinics, and Online Pharmacies

The rapid growth in demand for GLP-1 medications has created a complex prescribing landscape in the UK. NHS access for weight management specifically remains limited by capacity, waiting lists, and commissioning variability between Integrated Care Boards (ICBs). Many patients are therefore turning to private prescribers and online pharmacies.

If you are considering obtaining Mounjaro or Ozempic privately, it is essential to use a provider that is registered with the Care Quality Commission (CQC) and employs prescribers registered with the General Medical Council (GMC) or General Pharmaceutical Council (GPhC). Reputable services will require a medical consultation (which may be conducted remotely), review your medical history, check for contraindications, and provide ongoing monitoring. Be cautious of services that prescribe without adequate assessment, offer unusually low prices, or source medications from unverified suppliers. Counterfeit GLP-1 medications have been identified by the MHRA, and using unregulated products poses serious health risks. The NHS weight loss treatment page outlines the legitimate pathways for accessing obesity treatment through the health service.

For supplements, look for products manufactured in GMP-certified facilities and, ideally, those that have undergone independent third-party testing (such as through Informed Sport or NSF International). Be sceptical of supplements making dramatic weight loss claims, as the Advertising Standards Authority (ASA) has taken enforcement action against numerous misleading supplement advertisements in recent years.

Regardless of which option you are considering, the single most important step you can take is to speak with your GP or a qualified healthcare professional. They can assess your overall health, identify any contraindications, and help you develop a comprehensive weight management plan that is safe, realistic, and tailored to your individual needs.

Frequently Asked Questions

Is Mounjaro more effective than Ozempic for weight loss?

Based on the available clinical trial data, tirzepatide (Mounjaro) has demonstrated greater average weight loss than semaglutide (Ozempic/Wegovy) in head-to-head and cross-trial comparisons. In the SURMOUNT-1 trial, the highest dose of tirzepatide produced mean weight loss of 22.5%, compared to approximately 15% with semaglutide 2.4 mg in the STEP-1 trial. However, individual responses vary considerably, and the best medication for any given person depends on their full medical profile, tolerability, and treatment goals. Both medications represent substantial advances over previous pharmacological options.

Can I get Mounjaro or Ozempic on the NHS in the UK?

Ozempic is available on the NHS for the treatment of type 2 diabetes. Wegovy (semaglutide 2.4 mg) has received NICE approval for weight management and is available through specialist services, though access varies by region. Mounjaro is available on the NHS for type 2 diabetes and is being evaluated or available through specialist weight management pathways depending on local commissioning decisions. Eligibility typically requires a BMI of 35 or above (or 30+ with comorbidities) and prior engagement with behavioural weight management programmes. Private prescriptions are an alternative for those who do not meet NHS criteria or face long waiting times.

Are weight loss supplements a safe alternative to prescription medications?

Weight loss supplements available in the UK are generally safe when used as directed and purchased from reputable manufacturers. However, they are not equivalent alternatives to prescription medications in terms of efficacy. Supplements like glucomannan, green tea extract, and CLA produce modest weight loss of typically 1–3 kg, compared to the 15–22% body weight reductions seen with prescription incretin therapies. Supplements are regulated as foods, not medicines, meaning they undergo less rigorous safety testing. They may be appropriate for mildly overweight individuals seeking modest additional support, but they should not be used as a substitute for medical treatment in clinical obesity.

What are the most common side effects of Mounjaro and Ozempic?

The most frequently reported side effects of both medications are gastrointestinal in nature: nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These are typically most pronounced during the initial dose-escalation period and tend to improve over several weeks. Approximately 4–7% of clinical trial participants discontinued treatment due to side effects. More serious but rarer adverse events can include pancreatitis and gallbladder problems. Both medications require medical supervision and regular monitoring. Your prescribing clinician will guide you through the dose-escalation schedule to minimise side effects.

Will I regain weight if I stop taking Mounjaro or Ozempic?

Clinical trial evidence strongly suggests that significant weight regain occurs after discontinuation of both tirzepatide and semaglutide. In the SURMOUNT-4 trial, participants who switched from tirzepatide to placebo regained approximately 14% of body weight over one year. Similar patterns have been observed with semaglutide. This is consistent with the understanding of obesity as a chronic condition requiring ongoing management. For this reason, many clinicians recommend viewing these medications as long-term treatments rather than short-term fixes, combined with sustained lifestyle modifications to support weight maintenance.

How do I choose between Mounjaro, Ozempic, and supplements?

The choice depends on several factors: the severity of your weight concern, whether you have related conditions such as type 2 diabetes or cardiovascular disease, your budget, and your medical eligibility. If you have clinical obesity (BMI 30+) with comorbidities, prescription medications like Mounjaro or Ozempic offer the most robust evidence-based outcomes. If you are mildly overweight and looking for modest support alongside lifestyle changes, supplements may play a complementary role. In all cases, the recommended first step is to consult with your GP or a qualified healthcare professional who can assess your individual situation, discuss the benefits and risks, and help you access the most appropriate treatment pathway.